[go: up one dir, main page]

AU2018241654A1 - Method for preparing antibody-drug conjugate - Google Patents

Method for preparing antibody-drug conjugate Download PDF

Info

Publication number
AU2018241654A1
AU2018241654A1 AU2018241654A AU2018241654A AU2018241654A1 AU 2018241654 A1 AU2018241654 A1 AU 2018241654A1 AU 2018241654 A AU2018241654 A AU 2018241654A AU 2018241654 A AU2018241654 A AU 2018241654A AU 2018241654 A1 AU2018241654 A1 AU 2018241654A1
Authority
AU
Australia
Prior art keywords
group
antigen
binding protein
drug
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018241654A
Inventor
Zhi LIANG
Xun Liu
Yupeng Liu
Ruijun SHI
Piaoyang Sun
Weikang Tao
Lianshan Zhang
Xiaofei Zhang
Jin ZHONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of AU2018241654A1 publication Critical patent/AU2018241654A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A method for preparing an antibody-drug conjugate (ADC). In particular, the method mainly utilizes a combination of antibody biomolecules and an ion exchange carrier through electrostatic interaction to realize solid phase preparation of an ADC drug. Elution conditions are optimized, to control a drug-to-antibody coupling ratio (DAR) and separate a polymer-coupled drug, reduce the amount of a drug used in a coupling reaction, and enhance the targeted therapeutic effect of an ADC drug. The preparation method features fewer steps, simple operation, and programmable control, facilitating industrial scale-up production, and also realizing zero retention of reducing agents and organic solvents in the preparation process, significantly improving drug safety and reducing production costs.

Description

(57) Abstract: A method for preparing an antibody-drug conjugate (ADC). In particular, the method mainly utilizes a combination of antibody biomolecules and an ion exchange carrier through electrostatic interaction to realize solid phase preparation of an ADC drug. Elution conditions are optimized, to control a drug-to-antibody coupling ratio (DAR) and separate a polymer-coupled drug, reduce the amount of a drug used in a coupling reaction, and enhance the targeted therapeutic effect of an ADC drug. The preparation method features fewer steps, simple operation, and programmable control, facilitating industrial scale-up production, and also realizing zero retention of reducing agents and organic solvents in the preparation process, significantly improving drug safety and reducing production costs.

Claims (3)

1/6
Figure AU2018241654A1_C0008
Monoclonal antibody
Figure AU2018241654A1_C0009
Intermediate I
Crosslinker
Figure 1
Coupling ratio of crosslinker to antibody
Figure AU2018241654A1_C0010
Molar ratio of crosslinker to antibody
Figure 2
Figure AU2018241654A1_C0011
Intermediate I \H;OH KCL
Figure AU2018241654A1_C0012
Figure 3
1) immobilizing an antigen-binding protein on an ion exchange carrier to form an immobilized antigen-binding protein;
1. A method for preparing an antigen-binding protein-drug conjugate, wherein the method comprises the following steps:
2/6
Figure AU2018241654A1_C0013
Intermediate II
Antibody-drug conjugate
Figure 4
Figure AU2018241654A1_C0014
Conductivity (mS/cm)
Figure 5
2. The method of claim 1, wherein said ion exchange carrier is selected from the group consisting of ion exchange resins, ion exchange membranes, ion exchange fibers, preferably ion exchange resins.
3. The method of claims 1 or 2, wherein the ion exchange carrier is a cation exchange carrier, and the cation exchange carrier preferably contains a strongly acidic reaction ligand, and the strongly acidic reaction ligand is preferably a sulfonate.
4. The method of any one of claims 1 to 3, wherein the immobilized antigen-binding protein in step 2) is coupled to a drug, and the coupling reaction is that the antigen-binding protein and the drug are linked through an interaction between a nucleophilic group and an electrophilic group;
wherein the nucleophilic group is optionally from the antigen-binding protein or the drug, preferably from the antigen-binding protein;
wherein the electrophilic group is optionally from the antigen-binding protein or the drug, preferably from the drug.
5. The method of any one of claims 1 to 4, wherein the nucleophilic group is selected from the group consisting of a mercapto, a hydroxyl group, an amino group, a hydrazide, an oxime, a hydrazine, a thiosemicarbazone, a hydrazine carboxylate, and an aryl hydrazide group, provided that:
when the nucleophilic group is from the drug, the nucleophilic group is preferably a mercapto group;
when the nucleophilic group is from the antigen-binding protein, the nucleophilic group is preferably an amino group, a mercapto group, or a hydroxyl group; and the amino group is more preferably an N-terminal amino group, a side chain amino group, or an amino group of a saccharide in a glycosylated antigen-binding protein; the hydroxyl group is more preferably a hydroxyl group of a saccharide in a glycosylation antigen-binding protein, and the mercapto group is more preferably a thiol side chain , and most preferably a thiol side chain of a cysteine.
6. The method of any one of claims 1 to 5, wherein the antigen-binding protein-drug conjugate is coupled by a linker selected from a cleavable linker or an uncleavable linker.
7. The method of any one of claims 1 to 6, wherein the electrophilic group is selected from the group consisting of an active ester, a hydrocarbyl halide, a benzyl halide, an aldehyde, a ketone, a carboxyl group, and a maleimide group, provided that:
when the electrophilic group is from the antigen-binding protein, the electrophilic group is preferably derived from an aldehyde, a ketone, a carboxyl group, and a maleimide group, more preferably a maleimide group;
when the electrophilic group is from the drug, the electrophilic group is preferably an active ester, a hydrocarbyl halide, a maleimide group, more preferably a maleimide group; the active ester is preferably an NHS ester, an HOBt ester, a haloformate, an acid halide, and the hydrocarbyl halide is preferably a haloacetamide.
8. The method of any one of claims 1 to 7, wherein the electrophilic group is derived from the drug itself or from a modification of the drug.
9. The method of any one of claims 1 to 8, wherein the immobilized antigen-binding protein is coupled to a drug selected from the group consisting of lysine coupling, light-and-heavy interchain reductive disulfide bridge coupling, site-directed coupling, preferably lysine coupling, light-and-heavy chain reductive disulfide bridge coupling.
10. The method of any one of claims 1 to 9, wherein the antigen-binding protein in step 1) is optionally selected from a modified antigen-binding protein or an unmodified antigen-binding protein, preferably a modified antigen-binding protein; the modified antigen-binding protein is optionally an antigen-binding protein that binds a chemical reagent or crosslinker, preferably a modified antigen-binding protein that binds to the crosslinker;
wherein the drug in step 2) is optionally modified or unmodified, preferably modified.
11. The method of claim 10, wherein said crosslinker preferably has a compound of the following formula (L2):
O
Figure AU2018241654A1_C0001
T is selected from H, tert-butyl, acetyl, n-propionyl, isopropionyl, triphenylmethyl, methoxymethyl, 2-(trimethylsilyl) ethoxymethyl, preferably H or acetyl;
R15 is selected from the group consisting of a hydrogen atom, a halogen, a hydroxyl group, a cyano group, an alkyl group, an alkoxy group and a cycloalkyl group;
R16 is selected from the group consisting of alkyl, cycloalkyl and heterocyclic;
m is 0-5, preferably 1-3.
12. The method of claim 10, wherein said crosslinker represented by the formula (L2) is the compounds of the formula (L3):
O
Figure AU2018241654A1_C0002
(l3)
13. The method of claim 10, wherein the crosslinker has a maleimide group or a haloacetyl moiety;
wherein the crosslinker having a maleimide group is preferably selected from the group consisting of SMCC, LC-SMCC, KMUA, GMBS, EMCS, MBS, AMAS, SMPH, SMPB, and PMPI, more preferably SMCC;
the crosslinker bearing a haloacetyl moiety is preferably selected from the group consisting of SIAB, SIA, SBAand SBAP, more preferably SIAB.
14. The method of any one of claims 1 to 13, wherein the drug is selected from the group consisting of a toxin, a chemotherapeutic agent, a growth inhibitor, a tubulin inhibitor, an antibiotic, a radioisotope, and a cytotoxic agent.
15. The method of any one of claims 1 to 14, wherein the drug is selected from the group consisting of a maytansinnoid derivative, an auristatin derivative, a camptothecin alkaloid; wherein the maytansinoid derivative is preferably selected from DM1, DM3, DM4; the auristatin derivative is preferably selected from MMAE, MMAF; the camptothecin alkaloid is preferably selected from CPT, 10-hydroxy-CPT, CPT-11, SN-38 and topotecan, more preferably SN-38.
16. The method of any one of claims 1 to 15, wherein the drug is selected from the group consisting of a compound represented by the following formula (Dr):
Figure AU2018241654A1_C0003
°'R
Figure AU2018241654A1_C0004
or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
R, R^R7 are selected from the group consisting of a hydrogen atom, a halogen, a hydroxyl group, a cyano group, an alkyl group, an alkoxy group, and a cycloalkyl group;
at least one of R8-Rn is selected from the group consisting of halogen, alkenyl, alkyl and cycloalkyl, the remaining are hydrogen atoms;
or any two of R8-Rn form cycloalkyl groups, and the remaining two groups are selected from a hydrogen atom, an alkyl group and a cycloalkyl group;
R14 is selected from aryl or heteroaryl, and the aryl or heteroaryl is optionally further substituted with a substituent selected from the group consisting of a hydrogen atom, a halogen, a hydroxyl group, an alkyl group, an alkoxy group, and a cycloalkyl group;
R12-R13 are selected from a hydrogen atom, an alkyl group or a halogen;
preferably, wherein the formula (Dr) is a compound of the following formula (I):
HN (I)
17. The method of any one of claims 1 to 16, wherein the drug is a modified compound, preferably is a compound of the following formula (Li-Dr):
Figure AU2018241654A1_C0005
°R (Li-Dr) wherein, the Li structure is as follows:
O
Figure AU2018241654A1_C0006
° ; preferably MC;
n is 2-6, preferably 2-5;
R, R2-R7 are selected from the group consisting of a hydrogen atom, a halogen, a hydroxyl group, a cyano group, an alkyl group, an alkoxy group, and a cycloalkyl group;
at least one of R8-R*1 is selected from the group consisting of halogen, alkenyl, alkyl and cycloalkyl, the remaining are hydrogen atoms;
or any two of R8-Rn form a cycloalkyl group, and the remaining two groups are selected from a hydrogen atom, an alkyl group and a cycloalkyl group;
R12-R13 are selected from a hydrogen atom, an alkyl group or a halogen;
R14 is selected from aryl or heteroaryl, and the aryl or heteroaryl is optionally further substituted with a substituent selected from the group consisting of a hydrogen atom, a halogen, a hydroxyl group, an alkyl group, an alkoxy group, and a cycloalkyl group;
more preferably, wherein the formula (Li-Dr) is a compound represented by (II):
Figure AU2018241654A1_C0007
(II)
18. The method of claim 1, wherein the antigen-binding protein is selected from the group consisting of a humanized antibody, a murine antibody, a human antibody, a chimeric antibody, a single chain antibody, a bispecific antibody, preferably a humanized antibody.
19. The method of claim 1, wherein the antigen-binding protein is a monoclonal antibody or antigen binding fragment selected from the group consisting of Fab, F(ab')2, scFv fragments.
20. The method of any one of claims 1 to 19, wherein the antigen-binding protein binds to one or more polypeptides selected from the group consisting of HERZ, HER3, CD33, VEGF, VEGFR, VEGFR-2, CD 152, CD40, TNF, IL-1, IL-5, IL-17, IL-6R, IL-1, IL-2R, BLYS, OX40L, CTLA4, PCSK9, EGFR, c-Met, CD2, CD3, CDlla, CD19, CD30, CD38, CD20, CD52, CD60, CD80, CD86, TNF-α, IL-12, IL-17, IL-23, IL-6, IL-Ιβ, RSVF, IgE, RANK, BLyS, α4β7, PD-1, CCR4, SLAMF7, GD2, CD21, CD79b, IL20Ra, shortenin, CD22, CD79a, CD72, IGF-1R and RANKL, or antigen-binding fragments thereof; preferably EGFR, c-Met, or an antigen-binding fragment thereof.
21. The method according to any one of claims 1 to 2, wherein the antigen-binding protein is selected from the group consisting of: Humira (adalimumab), Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (Trastuzumab), Perjeta (Pertuzumab), Vectibix (Panibizumab), Theraloc (Netuzumab), Yervoy (Ipilimumab), Opdivo (Navolumab), Lucentis (Ranibizumab), Enbrel (Enacept), Myoscint (Imciromab pentetate), ProstaScint (Capromab pendetide), Remicade (Infliximab), ReoPro (Abciximab), Rituxan (rituximab), Simulect (Basiliximab), Synagis (Palivizumab), Verluma (Nofetumomab), Xolair (Omalizumab), Zenapax (Daclizumab), Cimzia (certolizumab), Zevalin (Ibritumomab), Orthoclone (Morommonab), Panorex (Edrecolomab), Mylotarg (Gemtuzumab), Soliris (Eculizumab), CNTO1275 (ustekinumab), Amevive (Alefacept), Raptiva (Efalizumab), Tysabri (Natalizumab), Actemra (Tocilizumab), Orencia (Abatacept), Arcalyst (Rilonacep), Stelara (Ustekinumab), Removab (Catumaxomab), Simponi (Golimumab), Haris (Canakinumab), Arzerra (Ofatumumab), Prolia (Denosumab), Benlysta (B elimumab), Nulojix (Belatacept), Eylea (Aflibercept), Campath (Alemtuzumab), CEA-Scan arcitumomab (fab fragment), Potelige (mogamulizumab), Abthrax (Raxibacumab), Gazyva (O binutuzumab), Lang Mu (Conbercept), Cyramza (Ramucirumab), Sylvant (Siltuximab), Entyvio (Vedolizumab), Keytruda (Pembrolizumab), Blincyto (Blinatumonab), Cosentyx (Secukinumab), Unituxin (Dinutuximab), Darzalex (Daratumumab), Praluent (Alirocumab), Repatha (Evolocumab), Portrazza (Necitumumab), Empliciti (Elotuzumab), Nucala (M epolizumab), Praxbind (Idarucizumab), Bexxar (Tositumomab and 1131 Tositumomab), or antigen-binding fragment thereof.
22. The method of any one of claims 1 to 21, wherein the antigen-binding protein is selected from the group consisting of an anti-EGFR antibody or antigen-binding fragment thereof, or an anti-c-Met antibody or antigen-binding fragment thereof;
wherein the anti-EGFR antibody or antigen-binding fragment thereof comprises LCDR1, LCDR2, LCDR3 region of SEQ ID N0:5, SEQ ID N0:6, SEQ ID N0:7, and variants thereof, HCDR1, HCDR2, HCDR3 region of SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10 and variants thereof, preferably sequence of light chain of SEQ ID NO:1, and heavy chain of SEQ ID N0:2;
alternatively, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises LCDR1, LCDR2, LCDR3 region of SEQ ID NO: 11 or SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, and variants thereof, preferably LCDR1 is SEQ ID NO: 17, and HCDR1, HCDR2, HCDR3 region of SEQ ID N0:14, SEQ ID N0:15, SEQ ID N0:16 and variants thereof; the c-Met antibody or antigen-binding fragment thereof preferably comprises sequence of light chain of SEQ ID N0:3 and heavy chain of SEQ ID N0:4.
23. The method of any of claims 1-22, wherein the conductivity of the antigen-binding protein of step 1) is adjusted to less than 5 mS/cm prior to contacting with the ion exchange carrier.
24. The method of any one of claims 1 to 23, wherein the antigen-binding protein described in the step 1) is immobilized on an ion exchange carrier in a buffer having a pH of 5.5 to 7.0, preferably 6.3.
25. The method of claim 24, wherein said buffer is selected from the group consisting of phosphate buffer, acetate buffer, citrate buffer, succinate buffer, preferably phosphate buffer.
26. The method of any one of claims 1 to 25, wherein the immobilized antigen-binding protein of step 2) is coupled to a drug, and a coupling reaction is carried out by slowly flowing the drug through the ion exchange carrier to control the molar ratio of the drug to the antigen-binding protein in an amount of less than 6:1 and a flow rate of 0.2-2 ml/min.
27. The method of any one of claims 1 to 26, wherein the eluting of step 2) comprises stepwise elution using buffers with different salt concentrations, the pH of the buffer is 5.0-6.5, preferably 5.5.
28. The method of claim 27, wherein the buffer is selected from the group consisting of phosphate buffer, acetate buffer, citrate buffer, succinate buffer, preferably citrate buffer.
29. The method of any one of claims 1 to 28, wherein the stepwise elution comprises a first step elution and a second step elution, wherein the salt concentration of the first elution is 100-140 mM, preferably 110 mM, the salt concentration of the second elution is 150-200 mM, preferably 180 mM.
30. The method of any of claims 1 to 29, wherein said step 1) comprises:
a) binding the antigen-binding protein to the crosslinker to obtain a modified antigen-binding protein;
b) immobilizing the modified antigen-binding protein on an ion exchange carrier to form a immobilized antigen-binding protein;
c) adding a deprotecting agent, and the deprotecting agent is preferably ISffHOH-HCL.
31. The method of claim 30, wherein the antigen-binding protein binds to the crosslinker at a temperature of 20 to 40 °C.
32. The method of claim 30, wherein the binding of the antigen-binding protein to the crosslinker is performed in a buffer having a pH of 4.0 to 5.5, preferably at a pH of 4.3; the buffer is preferably an acetate buffer, more preferably acetate buffer containing acetonitrile.
33. The method of any of claims 1 to 29, wherein said step 1) comprises:
A) immobilizing the antigen-binding protein on an ion exchange carrier to form a immobilized antigen-binding protein;
B) adding a reducing agent to reduce disulfide bridges of the immobilized antigen-binding protein;
wherein the reducing agent is preferably selected from the group consisting of TCEP, DTT, mercaptoethylamine, Ac-Cys, more preferably TCEP.
34. The method of claim 33, wherein the reduction reaction of step B is performed at a temperature 25 to 45°C, preferably 40°C.
2) contacting the immobilized antigen-binding protein with a drug to form an antigen-binding protein-drug conjugate;
3) eluting the antigen-binding protein-drug conjugate from the ion exchange carrier.
3/6
AU2018241654A 2017-03-30 2018-03-29 Method for preparing antibody-drug conjugate Abandoned AU2018241654A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201710202043.1 2017-03-30
CN201710202043 2017-03-30
CN201710233373.7 2017-04-11
CN201710233373 2017-04-11
CN201710342257.9 2017-05-16
CN201710342257 2017-05-16
PCT/CN2018/081080 WO2018177369A1 (en) 2017-03-30 2018-03-29 Method for preparing antibody-drug conjugate

Publications (1)

Publication Number Publication Date
AU2018241654A1 true AU2018241654A1 (en) 2019-11-07

Family

ID=63674287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018241654A Abandoned AU2018241654A1 (en) 2017-03-30 2018-03-29 Method for preparing antibody-drug conjugate

Country Status (12)

Country Link
US (1) US20200030453A1 (en)
EP (1) EP3603663A4 (en)
JP (1) JP2020518655A (en)
KR (1) KR20190133233A (en)
CN (1) CN110177569A (en)
AU (1) AU2018241654A1 (en)
BR (1) BR112019020174A2 (en)
CA (1) CA3058024A1 (en)
MX (1) MX2019011635A (en)
RU (1) RU2019134030A (en)
TW (1) TWI748078B (en)
WO (1) WO2018177369A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646873A1 (en) 2018-10-31 2020-05-06 Aprofol AG Folate salts
JP2022509156A (en) * 2018-11-30 2022-01-20 江蘇恒瑞医薬股▲ふん▼有限公司 Anti-CD40 antibody, its antigen-binding fragment, and its medical use
CN112206327A (en) * 2019-07-12 2021-01-12 上海药明生物技术有限公司 Preparation of antibody coupling drug and high-throughput screening method thereof
EP3999544A4 (en) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited Polypeptide complex for conjugation and use thereof
US20220402895A1 (en) * 2019-10-23 2022-12-22 National University Of Singapore Method and System for Synthesising Compounds
MX2022007312A (en) * 2019-12-16 2022-07-13 Jiangsu Hengrui Medicine Co Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof.
KR102153258B1 (en) * 2020-02-21 2020-09-07 프레스티지바이오로직스 주식회사 Optimized Method for Purification of Bevacizumab
CN111840571B (en) * 2020-08-03 2022-09-20 杭州皓阳生物技术有限公司 Antibody drug conjugate and application thereof
CN112285361B (en) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 Reagents to exclude interference from anti-CD38 monoclonal antibody drugs in anti-globulin detection
CN114409563B (en) * 2020-10-28 2023-11-10 中国科学院上海药物研究所 A type of linker for protein labeling and its application in biopharmaceuticals
CN114689880A (en) * 2020-12-25 2022-07-01 华为技术有限公司 Solid phase carrier, preparation method and application thereof, and biochip
WO2022152289A1 (en) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. An engineered antibody and antibody-drug conjugates comprisign same
CN113049811A (en) * 2021-03-22 2021-06-29 深圳市亚辉龙生物科技股份有限公司 Nano magnetic bead coating material, preparation method thereof, detection reagent and detection kit
CN113788951A (en) * 2021-10-08 2021-12-14 天津力博生物科技有限公司 Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof
TW202411249A (en) * 2022-05-20 2024-03-16 大陸商上海邁晉生物醫藥科技有限公司 Preparation method of antibody-drug conjugates
CN119585294A (en) * 2022-07-25 2025-03-07 南京金斯瑞生物科技有限公司 Method for site-directed synthesis of protein-active molecule conjugate
CN116003306B (en) * 2022-12-16 2024-09-10 成都普康唯新生物科技有限公司 Synthesis method of linker compound of maleimidocaprooic acid-PEGn analogue
CN117164701A (en) * 2022-12-27 2023-12-05 优洛生物(上海)有限公司 Engineered antibodies, methods of making and uses thereof
CN117180449B (en) * 2023-11-03 2024-04-02 正大天晴药业集团南京顺欣制药有限公司 Preparation method of antibody drug conjugate
CN118033123B (en) * 2024-02-28 2024-10-15 上海公安学院 Antibody and magnetic bead conjugate and coupling method thereof
CN118290514B (en) * 2024-06-05 2025-04-04 东曜药业有限公司 Purification method of antibody-drug conjugate based on anionic membrane and antibody-drug conjugate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200601182B (en) 2003-10-10 2007-04-25 Immunogen Inc Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BRPI0615049B1 (en) * 2005-08-24 2023-04-25 Immunogen, Inc PROCESS FOR THE PREPARATION OF AN ANTIBODY- MAITANSINOID CONJUGATE
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2009141384A2 (en) * 2008-05-21 2009-11-26 Novo Nordisk A/S Process for the purification of factor vii polypeptides using affinity resins comprising specific ligands
US9683012B2 (en) * 2011-12-15 2017-06-20 Prestige Biopharma Pte. Ltd. Method of antibody purification
US20150306242A1 (en) * 2012-10-04 2015-10-29 Immunogen, Inc. Process for preparing stable antibody maytansinoid conjugates
GB2513405A (en) * 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
RU2685728C2 (en) * 2014-01-29 2019-04-23 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Ligand-cytotoxic drug conjugate, production method and use thereof
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
GB2528643A (en) * 2014-07-08 2016-02-03 Adc Biotechnology Ltd Method of synthesising ADCs
CN104208719B (en) * 2014-09-24 2017-05-03 北京天广实生物技术股份有限公司 ADC (antibody-drug conjugate) cation exchange chromatographic purification method
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
US20180177890A1 (en) * 2015-02-15 2018-06-28 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and use thereof
CN106188293A (en) * 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof
CN106467575B (en) 2015-08-18 2020-07-31 四川百利药业有限责任公司 Cysteine engineered antibody-toxin conjugates

Also Published As

Publication number Publication date
US20200030453A1 (en) 2020-01-30
JP2020518655A (en) 2020-06-25
EP3603663A1 (en) 2020-02-05
TWI748078B (en) 2021-12-01
WO2018177369A1 (en) 2018-10-04
TW201837049A (en) 2018-10-16
CA3058024A1 (en) 2018-10-04
CN110177569A (en) 2019-08-27
EP3603663A4 (en) 2020-04-08
KR20190133233A (en) 2019-12-02
BR112019020174A2 (en) 2020-06-02
MX2019011635A (en) 2020-01-20
RU2019134030A (en) 2021-04-30

Similar Documents

Publication Publication Date Title
AU2018241654A1 (en) Method for preparing antibody-drug conjugate
ES2819870T3 (en) Modified J-chain binding molecules
US20230203201A1 (en) Binding molecules with modified j-chain
US11155596B2 (en) Polypeptide
EP3337812B1 (en) Method for the reduction of host cell proteins in affinity chromatography
CA2931356A1 (en) Bispecific antigen-binding constructs targeting her2
AU2014315744B2 (en) Method for obtaining APRIL-binding peptides, process for producing the peptides, APRIL-binding peptides obtainable with said method/process and use of the APRIL-binding peptides
Oitate et al. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method
EP3337818A1 (en) Affinity chromatography purification with low conductivity wash buffer
TW202200619A (en) Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof
WO2016031932A1 (en) METHOD FOR PRODUCING PROTEIN HAVING Fc REGION BY ALKALI WASHING
AU2018279278A1 (en) Methods of engineering surface charge for bispecific antibody production
CN115340606B (en) Antibody combined with human LAG-3 protein, encoding gene and application thereof
WO2020190834A1 (en) Compounds for inhibiting fucosylation and methods for using the same
CA3054833A1 (en) Composition comprising avelumab
KR102681811B1 (en) Novel anti-HER2 single chain variable fragment platform
US20240360225A1 (en) METHOD FOR PRODUCING ANTI-EGFR ANTIBODY, METHOD FOR IMPROVING AFFINITY FOR Fc¿RIIIa, AND ANTI-EGFR ANTIBODY
WO2024188339A1 (en) Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof
CA3177053A1 (en) Methods of treating cancer with anti-her2 biparatopic antibodies
Hui Engineering a light-activated protein domain for the site-specific conjugation of native IgGs

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period